Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 2, 2000, Pages 647-653

  Boichot, Elisabeth ^a   Wallace, John L ^b   Germain, Noëlla ^a   Corbel, Marianne ^a   Lugnier, Claire ^c   Lagente, Vincent ^a   Bourguignon, Jean Jacques ^d  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 N METHYL 9 PHENETHYL 2 TRIFLUOROMETHYLADENINE; 6 N,9 DIMETHYL 2 TRIFLUOROMETHYLADENINE; 9 (2 FLUOROBENZYL) 6 N METHYL 2 TRIFLUOROMETHYLADENINE; 9 (2 FLUOROBENZYL) 6 N METHYLADENINE; 9 SEC BUTYL 6 N METHYL 2 TRIFLUOROMETHYLADENINE; ADENINE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH ACID SECRETION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADENINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA; ARACHIDONIC ACID; BENZAMIDES; BRONCHOALVEOLAR LAVAGE FLUID; CATTLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXINS; HUMANS; ISOENZYMES; LEUKOCYTES, MONONUCLEAR; MICE; PENTAGASTRIN; PHOSPHODIESTERASE INHIBITORS; PYRIDINES; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033959661     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Alvarez R. Daniels DV, Shelton ER, Baecker PA, Fong AT, Devens B, Wilhem R, Eglen RM and Conti M (1996) An isoform-selective inhibitor of cyclic AMP-specific phosphodiesterase (PDE4) with anti-inflammatory properties, in Phosphodiesterase inhibitors: The Handbook of Immunopharmacology (Schudt C, Dent G and Rabe K eds) pp 160-184, Academic Press, San Diego.
2. 3H]rolipram binding. Biochem Pharmacol 51:949-956.
3. Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A and Torphy TJ (1998) SB 207499 (Ariflo), a potent and selective second-generation phosphodieterase 4 inhibitor: In vitro anti-inflammatory actions. J Pharmacol Exp Ther 284:420-426.
4. Barnette MS, Grous M, Cielinski LB, Burman M, Christensen SB and Torphy TJ (1995) Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: Correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 273:1396-1402.
5. Beavo JA (1995) Cylic nucleotide phosphodiesterases: Functional implications of multiples isoforms. Physiol rev 75:725-748.
6. Boichot E, Germain N, Lugnier C, Lagente V and Bourguignon JJ (1998) In vitro anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenines (Abstract). Am J Respir Crit Care Med 167:A141.
7. Bourguignon JJ, Désaubry L, Raboisson P, Wermuth CG and Lugnier C (1997) 9-Benzyladenines: Potent and selective cAMP phosphodiesterase inhibitors. J Med Chem 40:1768-1770.
8. Cavalla D and Frith R (1995) Phosphodiesterase IV inhibitors: Structural diversity and therapeutic potentials in asthma. Curr Med Chem 2:561-572.
9. 3H] rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 39:120-125.
10. Escofier N, Boichot E, Germain N, Silva PMR, Martins MA and Lagente V (1999) Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung. Fundam Clin Pharmacol 13:96-101.
11. Hichami A, Boichot E, Germain N, Berdyshev E, Coqueret O and Lagente V (1996) Phosphodiesterase 4 inhibitors and db-cAMP inhibit TNF-α release from human mononuclear cells: Effects of cAMP- and cGMP-dependent protein kinasc inhibitors. Med Inflamm 5:425-428.
12. Hichami A, Boichot E, Germain N, Legrand A, Moodley I and Lagente V (1995) Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells. Eur J Pharmacol 291:91-97.
13. Hughes B, Owens R, Perry M, Warrellow G and Allen R (1997) PDE-4 inhibitors: The use of molecular cloning in the design and development of novel drugs. Drug Dis Today 2:89-101.
14. Jacobitz S, McLaughlin MM, Livi GP, Burman M and Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 50:891-899.
15. Kambayashi T, Jacob CO, Zhou D, Mazurek N, Fong M and Strassmann G (1995) Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. J Immunol 155:4909-4916.
16. Karlsson JA, Souness J, Webber S, Pollock K and Raeburn D (1995) Anti-inflammatory effects of the novel phosphodiesterase IV inhibitor RP 73401. Int Arch Allergy Immunol 107:425-426.
17. Keravis TM, Wells JN and Hardman JG (1980) Cyclic nucleotide phosphodiesterase activities from pig coronary arteries: Lack of interconvertibility of major forms. Biochem Biophys Acta 613:116-129.
18. 3H]rolipram binding, and reserpine-induced hypothermia in mice. Drug Dev Res 135-142.
19. Lugnier C, Schoeffter P, Le Bec A, Strouthou E and Stoclet JC (1986) Selective inhibition of cyclic nucleotide phosphodiesterase of human, bovine and rat aorta. Biochem Pharmacol 35:1743-1751.
20. Parsons P, Worthen GS, Moir E, Tate R and Henson P (1989) The association of circulating endotoxin with the development of ARDS. Am Rev Respir Dis 140:294-301.
21. Prabhakar U, Lipshutz D, Bartus JO, Slivjak MJ, Smith EF, Lee JC and Esser KM (1994) Characterization of cAMP-dependent inhibition of LPS-induced TNF-alpha production by rolipram, a specific phosphodiesterase IV (PDEIV) inhibitor. Int J Immunopharmacol 16:805-816.
22. Puurunen J, Lucke C and Schwabe U (1978) Effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP. Naunyn-Schmiedeberg's Arch Pharmacol 304:69-75.
23. Rocque WJ, Holmes WD, Patel IR, Dougherty EW, Ittoop O, Overton L, Hoffman CR, Wisely GB, Willard DH and Luther MA (1997) Detailed characterization of a purified type-4 phosphodieterase, HSPDE4B2B: Differentiation of high affinity and low affinity (R)-rolipram binding. Prot Exp Purif 9:191-202.
24. Saccomano NA, Vinick FJ, Koe K, Nielsen JA, Whalen WM, Meltz M, Philips D, Thadieo PF, Jung S, Charpin DS, Lebel LA, Russo LL, Helwig DA, Johnson JL, Ives JL and Williams IH (1991) Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(Bicycloalkoxy)-4-methoxy-phenyl]-2-imidazolidinones. J Med Chem 34:291-298.
25. Schneider HH, Schmiechen R, Brezinski M and Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105-115.
26. Semmler J, Wachtel H and Endres S (1993) The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol 15:409-410.
27. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN and Karlsson JA (1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF-α generation from human monocytes by interacting with a low affinity' phosphodiesterase 4 conformer. Br J Pharmacol 118:649-658.
28. Souness JE, Houghton C, Sardar N and Withnall MT (1997) Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a low affinity phosphodiesterase 4 conformer. Br J Pharmacol 121:743-750.
29. Souness JE and Rao S (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9:227-236.
30. Teixeira MM, Gristwood RW, Cooper N and Hellewell PG (1997) Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future? Trends Pharmacol Sci 18: 164-170.
31. Tenor H and Schudt C (1996) Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods, in Phosphodiesterase Inhibitors: The Handbook of Immunopharmacology (Schudt C, Dent G and Rabe K eds) pp 160-184. Academic Press, San Diego.
32. Torphy TJ (1998) Phosphodiesterase isozymes: Molecular targets for novel anti-asthma agents. Am J Respir Crit Care Med 157:351-370.
33. Torphy TJ, DeWolf WE, Green DW and Livi GP (1993) Biochemical characteristics and cellular regulation of phosphodieterase IV. Agents Actions 43:S51-71.
34. Torphy TJ and Undem BJ (1991) Phosphodieterase inhibitors: New opportunities for the treatment of asthma. Thorax 46:512-523.
35. Torphy TJ, Zhou HL and Cielinski LB (1992) Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodieterase activity. J Pharmacol Exp Ther 263:1195-1205.
36. Turner C, Esser KM and Wheeldon EB (1993) Therapeutic intervention in a rat model of AHDS: IV. Phosphodiesterase IV inhibition. Circ Shock 39:237-245.
37. Wallace JL, Cucula M, Mugridge K and Parente L (1991) Secretagogue-specific effects of interleukin-1 on gastric secretion. Am J Physiol 24:G559-G564.
38. Worthen GS, Haslett C, Rees AJ, Gumbay RS, Henson JE and Henson PM (1987) Neutrophil-mediated pulmonary vascular injury: Synergistic effect of trace amounts of lipopolysaccharide and neutrophil stimuli on vascular permeability and neutrophil sequestration in the lung. Am Rev Respir Dis 136:19-28.